[Evaluation of the effects on the composition of alveolar surfactant of 2 chemotherapeutic protocols for carcinoma of the lung: peptichemio and MACC].
Balbi
B
B
Benatti
U
U
Morelli
A
A
Sacco
O
O
Vassallo
F
F
Rossi
G A
GA
Ravazzoni
C
C
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D001992:Bronchoalveolar Lavage Fluid / Q000032:analysis; D002277:Carcinoma / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D005227:Fatty Acids / Q000032:analysis; D005260:Female; D006801:Humans; D008130:Lomustine / Q000494:pharmacology / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008558:Melphalan / Q000031:analogs & derivatives*; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D010440:Peptichemio / Q000494:pharmacology* / Q000627:therapeutic use; D010743:Phospholipids / Q000032:analysis; D011663:Pulmonary Surfactants / Q000032:analysis / Q000187:drug effects*
D005227:Fatty Acids; D010743:Phospholipids; D011663:Pulmonary Surfactants; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D010440:Peptichemio; D008558:Melphalan; D008727:Methotrexate
Valutazione degli effetti sulla composizione del surfattante alveolare di due protocolli chemioterapici per il carcinoma polmonare: peptichemio e MACC.